RBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $450. Earlier Biogen reported Q3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results October 21, 2015 1:42 PM Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat October 21, 2015 1:36 PM Biogen to cut 11 percent of staff, cancel some drug programs; stock jumpsOctober 21, 2015 7:45 AM Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS OutlookOctober 21, 2015 7:31 AM Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MSOctober 21, 2015 7:31 AM